Iris Fernández-Lázaro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Iris Fernández-Lázaro has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
- Ana Beatriz Gago-Veiga
Headache Unit, Department of Neurology, Hospital Universitario de la Princesa, Madrid, Spain
4 shared publications Alberto Lozano Ros
Headache Unit, Department of Neurology Gregorio Marañón University Hospital Madrid Spain
3 shared publications- Alex Jaimes
Headache Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
3 shared publications Germán Latorre
Headache Unit, Department of Neurology, Hospital Universitario de Fuenlabrada, Madrid, Spain
3 shared publicationsLeonardo Portocarrero-Sánchez
Headache Unit, Department of Neurology, Hospital Universitario La Paz, Madrid, Spain
3 shared publicationsSonia Santos Lasaosa
Hospital Clínico Universitario Lozano Blesa
3 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Springer Nature in The Journal of Headache and Pain
Long-term atogepant for treatment-resistant migraine in real-world clinical practice: 12-month results (gema project)
Background: Short- and mid-term real-world data support the effectiveness of atogepant for migraine prevention, but evidence beyond 6 months remains scarce. This study evaluated the 12-month effectiveness, safety, persistence, and predictors of response in a large treatment-resistant migraine cohort. Methods: This prospective multicentre study enrolled patients from 15 tertiary Headache Units in Spain within the GEMA Project. Clinical and demographic characteristics, previous and concomitant preventive treatments, monthly headache days (MHD), monthly migraine days (MMD), and adverse events were systematically collected at baseline and after 3, 6, and 12 months. In a subset of patients, Headache Impact Test (HIT-6), Hospital Anxiety and Depression Scale (HADS), and Insomnia Severity Index (ISI) were also assessed. Results: A total of 513 patients were included. The cohort showed marked treatment resistance, with a median of 6 previous preventive failures; 74% ( n = 380) had chronic migraine, 84% ( n = 423) had previously failed onabotulinumtoxinA, and more than half had prior exposure to anti-CGRP monoclonal antibodies ( n = 270). Treatment persistence was approximately 80% at 6 months ( n = 409) and 60% at 12 months ( n = 304), with lack of effectiveness as the main reason for discontinuation. Among patients remaining on treatment with complete data at all follow-up visits, median MHD decreased from 20 days at baseline to 10 days at 3 months and 9 days at 6 months, remaining stable at 9 days at 12 months. Median MMD decreased from 13 days to 6 days at 3 months, 5 days at 6 months, and remained at 5 days at 12 months ( p < 0.0001 versus baseline for all time points). At 12 months, ≥ 50% response rates were 52.3% for MHD and 57.8% for MMD in the observed-case analysis, and approximately 31% and 33%, respectively, using non-responder imputation in the full baseline cohort. Improvements in disability and medication overuse were observed, while exploratory analyses in smaller subsets suggested improvements in anxiety, depression, and insomnia. A greater burden of previous preventive treatment failures independently predicted lower odds of achieving a ≥ 50% response at 12 months. The frequency of most reported adverse events was lower at later follow-up visits, and no new safety signals emerged. Conclusions: Atogepant was associated with maintained clinical benefit over 12 months among patients who remained on treatment, with a favourable long-term safety profile in a highly treatment-resistant migraine population. Greater previous preventive failure burden predicted lower response rates, reinforcing the importance of earlier preventive optimisation. Trial registration: ClinicalTrials.gov, NCT07699549, retrospectively registered on 8th of July 2026.
- 15 September 2026
- Published by Springer Nature in The Journal of Headache and Pain
Open AccessLong-term atogepant for treatment-resistant migraine in real-world clinical practice: 12-month results (gema project)
Background: Short- and mid-term real-world data support the effectiveness of atogepant for migraine prevention, but evidence beyond 6 months remains scarce. This study evaluated the 12-month effectiveness, safety, persistence, and predictors of response in a large treatment-resistant migraine cohort. Methods: This prospective multicentre study enrolled patients from 15 tertiary Headache Units in Spain within the GEMA Project. Clinical and demographic characteristics, previous and concomitant preventive treatments, monthly headache days (MHD), monthly migraine days (MMD), and adverse events were systematically collected at baseline and after 3, 6, and 12 months. In a subset of patients, Headache Impact Test (HIT-6), Hospital Anxiety and Depression Scale (HADS), and Insomnia Severity Index (ISI) were also assessed. Results: A total of 513 patients were included. The cohort showed marked treatment resistance, with a median of 6 previous preventive failures; 74% ( n = 380) had chronic migraine, 84% ( n = 423) had previously failed onabotulinumtoxinA, and more than half had prior exposure to anti-CGRP monoclonal antibodies ( n = 270). Treatment persistence was approximately 80% at 6 months ( n = 409) and 60% at 12 months ( n = 304), with lack of effectiveness as the main reason for discontinuation. Among patients remaining on treatment with complete data at all follow-up visits, median MHD decreased from 20 days at baseline to 10 days at 3 months and 9 days at 6 months, remaining stable at 9 days at 12 months. Median MMD decreased from 13 days to 6 days at 3 months, 5 days at 6 months, and remained at 5 days at 12 months ( p < 0.0001 versus baseline for all time points). At 12 months, ≥ 50% response rates were 52.3% for MHD and 57.8% for MMD in the observed-case analysis, and approximately 31% and 33%, respectively, using non-responder imputation in the full baseline cohort. Improvements in disability and medication overuse were observed, while exploratory analyses in smaller subsets suggested improvements in anxiety, depression, and insomnia. A greater burden of previous preventive treatment failures independently predicted lower odds of achieving a ≥ 50% response at 12 months. The frequency of most reported adverse events was lower at later follow-up visits, and no new safety signals emerged. Conclusions: Atogepant was associated with maintained clinical benefit over 12 months among patients who remained on treatment, with a favourable long-term safety profile in a highly treatment-resistant migraine population. Greater previous preventive failure burden predicted lower response rates, reinforcing the importance of earlier preventive optimisation. Trial registration: ClinicalTrials.gov, NCT07699549, retrospectively registered on 8th of July 2026.
- Open Access
- 6 July 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (7)
Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project)
Background: Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for both acute and preventive treatment of episodic migraine. Real-world data on its preventive use remain limited, particularly in patients with multiple prior preventive failures. This study evaluated the effectiveness and tolerability of rimegepant in routine clinical practice, focusing on a highly treatment-resistant population. Methods: We conducted a prospective, multicenter real-world cohort study within the GEMA (GEpants in MigrAine) Project across nine tertiary Headache Units in Spain. Adults initiating rimegepant for migraine prevention were consecutively enrolled and followed for up to 6 months. The primary endpoint was the 3-month change in monthly headache days (MHD). Secondary endpoints included the change in monthly migraine days (MMD), response rates, predictors of response, and tolerability. Baseline characteristics, prior preventive failures, medication overuse, adverse events, and patient-reported outcomes (Headache Impact Test-6 (HIT-6), HADS, and Insomnia Severity Index) were recorded. Results: In total, 150 patients completed 3-month follow-up and 64 reached 6 months. The cohort was predominantly female (85.3%), with 70.7% episodic migraine, a median age of 48 years (interquartile range (IQR) = 39–57), and a median of 6 prior preventive failures (IQR = 4–8), reflecting high treatment resistance. At 3 months, median MHD decreased from 12 to 7.5 and MMD from 10 to 6 ( p < 0.05), with significant improvement in HIT-6. Overall, 36% and 43% achieved ≥ 50% reduction in MHD and MMD, respectively (≥ 75%: 15% and 20%). Among patients with 6-month data, further reductions were observed (MHD, 6 days; MMD, 5 days), with ≥ 50% response rates increasing to 48% and 58%. Clinical responders showed greater improvements in anxiety and depressive symptoms. Medication overuse, chronic migraine, and prior exposure to anti-CGRP monoclonal antibodies and onabotulinumtoxinA were independent predictors of poorer outcomes, with response declining with increasing prior anti-CGRP exposure, although a relevant proportion still achieved meaningful benefit. Rimegepant was well tolerated, with predominantly mild adverse events (nausea 13%, constipation 8%) and low discontinuation (7% at 3 months), and with nausea being the most frequent cause. Conclusions: Rimegepant showed meaningful preventive effectiveness and good tolerability in routine clinical practice, including in highly treatment-resistant patients with prior anti-CGRP monoclonal antibody exposure. The response was influenced by baseline disease burden and prior treatment exposure. These findings suggest that earlier use of rimegepant in the treatment course may be associated with greater clinical benefit.
- 6 July 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (7)
Open AccessRimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project)
Background: Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for both acute and preventive treatment of episodic migraine. Real-world data on its preventive use remain limited, particularly in patients with multiple prior preventive failures. This study evaluated the effectiveness and tolerability of rimegepant in routine clinical practice, focusing on a highly treatment-resistant population. Methods: We conducted a prospective, multicenter real-world cohort study within the GEMA (GEpants in MigrAine) Project across nine tertiary Headache Units in Spain. Adults initiating rimegepant for migraine prevention were consecutively enrolled and followed for up to 6 months. The primary endpoint was the 3-month change in monthly headache days (MHD). Secondary endpoints included the change in monthly migraine days (MMD), response rates, predictors of response, and tolerability. Baseline characteristics, prior preventive failures, medication overuse, adverse events, and patient-reported outcomes (Headache Impact Test-6 (HIT-6), HADS, and Insomnia Severity Index) were recorded. Results: In total, 150 patients completed 3-month follow-up and 64 reached 6 months. The cohort was predominantly female (85.3%), with 70.7% episodic migraine, a median age of 48 years (interquartile range (IQR) = 39–57), and a median of 6 prior preventive failures (IQR = 4–8), reflecting high treatment resistance. At 3 months, median MHD decreased from 12 to 7.5 and MMD from 10 to 6 ( p < 0.05), with significant improvement in HIT-6. Overall, 36% and 43% achieved ≥ 50% reduction in MHD and MMD, respectively (≥ 75%: 15% and 20%). Among patients with 6-month data, further reductions were observed (MHD, 6 days; MMD, 5 days), with ≥ 50% response rates increasing to 48% and 58%. Clinical responders showed greater improvements in anxiety and depressive symptoms. Medication overuse, chronic migraine, and prior exposure to anti-CGRP monoclonal antibodies and onabotulinumtoxinA were independent predictors of poorer outcomes, with response declining with increasing prior anti-CGRP exposure, although a relevant proportion still achieved meaningful benefit. Rimegepant was well tolerated, with predominantly mild adverse events (nausea 13%, constipation 8%) and low discontinuation (7% at 3 months), and with nausea being the most frequent cause. Conclusions: Rimegepant showed meaningful preventive effectiveness and good tolerability in routine clinical practice, including in highly treatment-resistant patients with prior anti-CGRP monoclonal antibody exposure. The response was influenced by baseline disease burden and prior treatment exposure. These findings suggest that earlier use of rimegepant in the treatment course may be associated with greater clinical benefit.
- Open Access
- 25 June 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (6) , e71560
ESTELA‐Study: Long‐Term Effectiveness and Safety of Anti‐Calcitonin Gene‐Related Peptide Monoclonal Antibodies in Real‐World Clinical Practice
Background: Anti‐CGRP antibodies are effective and safe in real‐world migraine management, but guidelines recommend discontinuation after 12–18 months due to limited long‐term data and remaining uncertainties regarding optimal treatment duration and sustained safety, highlighting the need for large‐scale long‐term real‐world evidence. This study evaluated their safety and effectiveness in patients treated for ≥2 years. Methods: This multicenter retrospective study included patients from 13 headache units who received the same anti‐CGRP antibody for ≥24 months, excluding discontinuation periods. Baseline characteristics, monthly headache days (MHD), monthly migraine days (MMD), and adverse events (AEs) were recorded at baseline, 6 months, 1, 2, 3, and 4 years. Descriptive statistics were used to summarize clinical characteristics, and appropriate parametric or non‐parametric tests were applied for group comparisons. Multivariate analyses were performed to explore associations between baseline variables and long‐term treatment response. Results: A total of 454 patients (91% female, mean age 48) were analyzed, with follow‐up at 2 years ( n = 454), 3 years ( n = 135), and 4 years ( n = 17). Treatments included erenumab (39%), galcanezumab (34%), and fremanezumab (27%). Fifty‐seven percent maintained continuous therapy, while 43% restarted after discontinuation. Sustained reductions in MHD and MMD were observed at 2, 3, and 4 years (MHD from 20 to 6, 6, 5/MMD from 14 to 4, 4, and 2). Medication overuse decreased from 78% to 13%, 20%, and 18%. Loss of effectiveness occurred in 4.2% after 2 years. AEs appeared in 80%), leading to discontinuation in 0.4%. Multivariate analysis showed that shorter disease duration prior to anti‐CGRP initiation, earlier anti‐CGRP initiation, and greater MHD/MMD reduction at 6 months were associated with better long‐term outcomes. Conclusions: Anti‐CGRP mAbs demonstrate sustained long‐term safety and effectiveness, with consistent reduction in headache and migraine days and lower medication overuse. Early initiation and greater initial improvement predict better long‐term outcomes. Findings support extending therapy beyond 12–18 months, supporting optimization of clinical protocols.
- 25 June 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (6) , e71560
Open AccessESTELA‐Study: Long‐Term Effectiveness and Safety of Anti‐Calcitonin Gene‐Related Peptide Monoclonal Antibodies in Real‐World Clinical Practice
Background: Anti‐CGRP antibodies are effective and safe in real‐world migraine management, but guidelines recommend discontinuation after 12–18 months due to limited long‐term data and remaining uncertainties regarding optimal treatment duration and sustained safety, highlighting the need for large‐scale long‐term real‐world evidence. This study evaluated their safety and effectiveness in patients treated for ≥2 years. Methods: This multicenter retrospective study included patients from 13 headache units who received the same anti‐CGRP antibody for ≥24 months, excluding discontinuation periods. Baseline characteristics, monthly headache days (MHD), monthly migraine days (MMD), and adverse events (AEs) were recorded at baseline, 6 months, 1, 2, 3, and 4 years. Descriptive statistics were used to summarize clinical characteristics, and appropriate parametric or non‐parametric tests were applied for group comparisons. Multivariate analyses were performed to explore associations between baseline variables and long‐term treatment response. Results: A total of 454 patients (91% female, mean age 48) were analyzed, with follow‐up at 2 years ( n = 454), 3 years ( n = 135), and 4 years ( n = 17). Treatments included erenumab (39%), galcanezumab (34%), and fremanezumab (27%). Fifty‐seven percent maintained continuous therapy, while 43% restarted after discontinuation. Sustained reductions in MHD and MMD were observed at 2, 3, and 4 years (MHD from 20 to 6, 6, 5/MMD from 14 to 4, 4, and 2). Medication overuse decreased from 78% to 13%, 20%, and 18%. Loss of effectiveness occurred in 4.2% after 2 years. AEs appeared in 80%), leading to discontinuation in 0.4%. Multivariate analysis showed that shorter disease duration prior to anti‐CGRP initiation, earlier anti‐CGRP initiation, and greater MHD/MMD reduction at 6 months were associated with better long‐term outcomes. Conclusions: Anti‐CGRP mAbs demonstrate sustained long‐term safety and effectiveness, with consistent reduction in headache and migraine days and lower medication overuse. Early initiation and greater initial improvement predict better long‐term outcomes. Findings support extending therapy beyond 12–18 months, supporting optimization of clinical protocols.
- 23 June 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (12) , e214945
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine
- 23 June 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (12) , e214945
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine
- Open Access
- 28 May 2026
- Published by IMR Press in Revista De Neurologia
- Vol. 81 (5) , 51129
Effectiveness and Risk of Recurrence of Pulsed Radiofrequency in Trigeminal Neuralgia and Chronic Cluster Headache
Introduction: Percutaneous pulsed radiofrequency (PPRF) is a minimally invasive neuromodulation technique used in chronic pain management. Our aim was to evaluate its effectiveness and safety in refractory cases of trigeminal neuralgia (TN) and chronic cluster headache (CH). Methods: We conducted a retrospective study of patients with TN and CH diagnosed according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria and treated with PPRF (Gasserian ganglion for TN and sphenopalatine ganglion for CH) over an 8-year period. Effectiveness at 3 months was assessed by evaluating reduction in the number of pain days in TN and number of attacks in CH, ≥50% response rate, visual analogue scale (VAS), Patient Global Impression of Improvement (PGI-I), and pain recurrence. Results: Twenty-five patients met the inclusion criteria, including 19 with TN and 6 with CH, with a mean age of 76 and 52 years, respectively. Clinical improvement was observed in 14/19 (73.6%) patients with TN and 5/6 (83.3%) patients with CH. A ≥50% response rate was achieved in 11/14 (78.6%) patients with TN and 4/6 (66.7%) patients with CH. VAS scores decreased at 3 months in both groups (p < 0.0001 in TN; p = 0.06 in CH). PGI-I was rated as “better” or “much better” in 10/19 (52.6%) patients with TN and 5/6 (83.3%) patients with CH. Pain recurrence occurred in 13/14 (92.8%) patients with TN and 5/5 (100%) patients with CH, mainly after 1 year following the first procedure (7/13 TN and 2/5 CH). No major adverse events were reported. Conclusions: In our series, PPRF appears to be an effective and safe treatment for refractory TN and CH. Although the study is retrospective and the sample size is limited, particularly in CH, these findings should be considered preliminary but clinically relevant. Despite the high recurrence rate, given its low complication profile, it may represent a treatment option for patients who are not candidates for surgical procedures.
- 28 May 2026
- Published by IMR Press in Revista De Neurologia
- Vol. 81 (5) , 51129
Open AccessEffectiveness and Risk of Recurrence of Pulsed Radiofrequency in Trigeminal Neuralgia and Chronic Cluster Headache
Introduction: Percutaneous pulsed radiofrequency (PPRF) is a minimally invasive neuromodulation technique used in chronic pain management. Our aim was to evaluate its effectiveness and safety in refractory cases of trigeminal neuralgia (TN) and chronic cluster headache (CH). Methods: We conducted a retrospective study of patients with TN and CH diagnosed according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria and treated with PPRF (Gasserian ganglion for TN and sphenopalatine ganglion for CH) over an 8-year period. Effectiveness at 3 months was assessed by evaluating reduction in the number of pain days in TN and number of attacks in CH, ≥50% response rate, visual analogue scale (VAS), Patient Global Impression of Improvement (PGI-I), and pain recurrence. Results: Twenty-five patients met the inclusion criteria, including 19 with TN and 6 with CH, with a mean age of 76 and 52 years, respectively. Clinical improvement was observed in 14/19 (73.6%) patients with TN and 5/6 (83.3%) patients with CH. A ≥50% response rate was achieved in 11/14 (78.6%) patients with TN and 4/6 (66.7%) patients with CH. VAS scores decreased at 3 months in both groups (p < 0.0001 in TN; p = 0.06 in CH). PGI-I was rated as “better” or “much better” in 10/19 (52.6%) patients with TN and 5/6 (83.3%) patients with CH. Pain recurrence occurred in 13/14 (92.8%) patients with TN and 5/5 (100%) patients with CH, mainly after 1 year following the first procedure (7/13 TN and 2/5 CH). No major adverse events were reported. Conclusions: In our series, PPRF appears to be an effective and safe treatment for refractory TN and CH. Although the study is retrospective and the sample size is limited, particularly in CH, these findings should be considered preliminary but clinically relevant. Despite the high recurrence rate, given its low complication profile, it may represent a treatment option for patients who are not candidates for surgical procedures.
- Top Cited Papers
- 24 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (4) , e214659
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine
The aim of this study was to describe the long-term effectiveness and treatment persistence of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) in migraine and to identify baseline factors associated with 2-year treatment continuation. A prospective observational multicenter registry-based study of anti-CGRP MAbs was conducted. We analyzed changes in monthly headache days (MHDs) at 24 months (M24) compared with baseline in those who reached M24 (ON-group). We analyzed patterns of response at 4 time points (6, 12, 18, and 24 months). We defined sustained response (SR) as a ≥50% reduction in MHDs at ≥3 of 4 time points. We compared baseline characteristics of the ON-group with those of the discontinuation group because of lack of effectiveness (OFF-group). A total of 1,340 individuals reached M24 (ON-group: median age 48.0 [41.0-55.0] years; 81.7% female). The median MHD at baseline was 20.0 (13.0-28.0) days. At M24, 60.4% of patients demonstrated ≥50% reduction in MHDs (809/1,340). The proportion of participants achieving SR at M24 was 53.8% (142/264). When compared with the ON-group (n = 1,340), the OFF-group (n = 1,057) showed statistically significant higher baseline MHDs (ON: 20.0 [13.0-28.0] vs OFF: 25.0 [16.0-28.0]) and a greater proportion of patients with aura (ON: 16.2% vs OFF: 22.9%), depression (ON: 22.8% vs OFF: 37.9%), and obesity (ON: 7.2% vs OFF: 19.1%) (p < 0.001). Sustained reductions in MHDs to anti-CGRP treatment at 2 years was observed. Delayed treatment onset, migraine with aura, depression, and obesity may negatively affect treatment persistence. This study provides Class IV evidence that, in patients with migraine, treatment with anti-CGRP MAbs is associated with sustained reductions in MHDs over a 24-month period.
- 24 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (4) , e214659
Top Cited PapersLong-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine
The aim of this study was to describe the long-term effectiveness and treatment persistence of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) in migraine and to identify baseline factors associated with 2-year treatment continuation. A prospective observational multicenter registry-based study of anti-CGRP MAbs was conducted. We analyzed changes in monthly headache days (MHDs) at 24 months (M24) compared with baseline in those who reached M24 (ON-group). We analyzed patterns of response at 4 time points (6, 12, 18, and 24 months). We defined sustained response (SR) as a ≥50% reduction in MHDs at ≥3 of 4 time points. We compared baseline characteristics of the ON-group with those of the discontinuation group because of lack of effectiveness (OFF-group). A total of 1,340 individuals reached M24 (ON-group: median age 48.0 [41.0-55.0] years; 81.7% female). The median MHD at baseline was 20.0 (13.0-28.0) days. At M24, 60.4% of patients demonstrated ≥50% reduction in MHDs (809/1,340). The proportion of participants achieving SR at M24 was 53.8% (142/264). When compared with the ON-group (n = 1,340), the OFF-group (n = 1,057) showed statistically significant higher baseline MHDs (ON: 20.0 [13.0-28.0] vs OFF: 25.0 [16.0-28.0]) and a greater proportion of patients with aura (ON: 16.2% vs OFF: 22.9%), depression (ON: 22.8% vs OFF: 37.9%), and obesity (ON: 7.2% vs OFF: 19.1%) (p < 0.001). Sustained reductions in MHDs to anti-CGRP treatment at 2 years was observed. Delayed treatment onset, migraine with aura, depression, and obesity may negatively affect treatment persistence. This study provides Class IV evidence that, in patients with migraine, treatment with anti-CGRP MAbs is associated with sustained reductions in MHDs over a 24-month period.